Home » US FDA Considers Disclosing Data From Pending, Withdrawn NDAs
US FDA Considers Disclosing Data From Pending, Withdrawn NDAs
November 16, 2009
The U.S. Food and Drug Administration (FDA) may begin disclosing safety and efficacy data in pending and withdrawn NDAs after a report with recommendations
on such disclosures is released early next year by the FDA Transparency Task Force.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor